MedTrace Logo

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).

NCT02321046 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2020-06-29

No results posted yet for this study

Summary

This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with cytologically verified advanced NSCLC in Russia.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Alexander Bedenkov, MCMD · AstraZeneca

  • Konstantin Lactionov, Professor · Russian Cancer Research Center named after N.N.Blokhin

  • Irina Demidova, PHD · Moscow City Clinical Cancer Hospital #62

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-02
Primary Completion
2019-06-28
Completion
2019-06-28

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321046 on ClinicalTrials.gov